Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment

Table 1

Demographics of included patients.

Number of patients (eyes)	15 (17)
Age (years)	49.24 ± 7.70
Sex (male/female)	10/5
Symptom duration (months)	4.00 ± 3.04
Follow-up duration (months)	17.09 ± 6.40
Steroid dose (mg)	15.59 ± 5.58
Steroid use duration (months)	8.94 ± 9.03
Spironolactone dose (mg)	50
Spironolactone use duration (months)	2.59 ± 1.19
Underlying disease
Myasthenia gravis (%)	8 (47.1)
Glomerular nephritis (%)	5 (29.4)
After organ transplantation (%)	4 (23.5)